Regeneron Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals

REGN 695.46

+2.0%

Nov 13 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Miljenko Zuanic who wrote (2660)	3/4/2019 12:28:36 PM
From: Miljenko Zuanic	Read Replies (1) of 3557

Another AAV-GT acquisition, field ophthalmology (rare diseases): investors.biogen.com I know for recent bad experience with ADVM (Avalanche, 2016) sub-retinal AAV AMD failure (biter taste stay for long time), growing interest for gene-therapy trigger today another acquisition. ADMV, with its AMD gene therapy candidate (AAV-aflibercept, or AAV-Eylea) is something that REGN should (and it does) keep near chest.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next